Biodesix: Kieran O'Kane, Bobbi Coffin
Biodesix has announced a realignment of its commercial executive team. Effective immediately, current head of strategic marketing Kieran O'Kane will become the company's chief commercial officer, while Bobbi Coffin, currently chief marketing officer, will become the firm's chief growth officer.
After joining the company in 2018, Biodesix said that O'Kane played a leading role in the successful acquisition of Integrated Diagnostics and Oncimmune's laboratory and incidental pulmonology nodule malignancy test, proving instrumental in the subsequent commercial launch of what are now the Nodify XL2 and Nodify CDT tests. He previously worked at various other companies, including NanoString Technologies, Bristol Myers Squibb, and Roche.
Coffin joined Biodesix in 2015 from Exact Sciences where she was VP of commercial marketing and strategy. Prior to that role, she held leadership positions at Precision Therapeutics and Cytyc/Hologic.